#Baricitinib

Matt McCarthy

DrMattMcCarthy

UPDATE: COVID medicine has changed substantially over the past few months. The questions we're grappling with today are very different than the ones we were dealing with just a few

Francisco Marty, MD

FranciscoMarty_

It took a while to digest the details of over 600 pages, but here is my review and comparative analysis of the #ACTT2 trial that compared #baricitinib vs. #placebo among

el gato malo

boriquagato

this study looks important:it was controlled, prospective study. it's showing a stunning 71% mortality benefit in moderate to severe covid-19 cases even in the very old.remdesivir shows no morality benefit.baricitinib

Erin McCreary

ErinMcCreary

With the Jan 7th announcement of the @remap_cap IL-6ra results: https://www.medrxiv.org/content/10.1101/2021.01.07.21249390v2 and last nights @BMJ_Latest RCT drop: https://www.bmj.com/content/372/bmj.n84let’s talk about tocilizumab [threa

By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.